{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:36:01Z","timestamp":1791232561305,"version":"4.1.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Roche"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>PIK3CA mutations are common in HR+\/HER2\u2212 metastatic breast cancer and guide the use of PI3K-targeted therapies. This expert consensus provides recommendations on timing, methods, and interpretation of PIK3CA testing, emphasizing early assessment at metastatic diagnosis, preferred use of NGS panels, and standardized pre-analytical workflows. Reflex and dual-sample strategies can reduce delays and failures. Implementation requires coordinated logistics, education across the diagnostic chain, and equitable access to ensure timely, personalized treatment.<\/jats:p>","DOI":"10.1038\/s41523-026-00968-3","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:24:13Z","timestamp":1778873053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Expert recommendations for PIK3CA testing in HR+\/HER2\u2212 locally advanced and metastatic breast cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Caterina","family":"Marchi\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen R.","family":"Copson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Fremd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"968_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari, A. et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 32, 1475\u20131495 (2021).","journal-title":"Ann. Oncol."},{"key":"968_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00523-4","volume":"9","author":"R Patel","year":"2023","unstructured":"Patel, R., Klein, P., Tiersten, A. & Sparano, J. A. An emerging generation of endocrine therapies in breast cancer: a clinical perspective. NPJ Breast Cancer 9, 20 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"968_CR3","doi-asserted-by":"crossref","unstructured":"Jhaveri, K. & Marm\u00e9, F. Current and emerging treatment approaches for hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer. Cancer Treat. Rev. 123, 102670 (2024).","DOI":"10.1016\/j.ctrv.2023.102670"},{"key":"968_CR4","unstructured":"Gennari, A. et al. ESMO Living Guideline: Metastatic Breast Cancer v1.2. Accessed on 11 May 2026. Available from: https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-metastatic-breast-cancer (2025)."},{"key":"968_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar, W. J. et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 22, 331\u2013357 (2024).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"968_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000514561","volume":"16","author":"A Mavratzas","year":"2021","unstructured":"Mavratzas, A. & Marm\u00e9, F. Treatment of luminal metastatic breast cancer beyond CDK4\/6 inhibition: is there a standard of care in clinical practice? Breast Care 16, 115\u2013128 (2021).","journal-title":"Breast Care"},{"key":"968_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2217\/fon-2018-0942","volume":"16","author":"A Frassoldati","year":"2020","unstructured":"Frassoldati, A. et al. Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. Future Oncol. 16, 129\u2013145 (2020).","journal-title":"Future Oncol."},{"key":"968_CR8","first-page":"5","volume":"2025","author":"JM Cejalvo And\u00fajar","year":"2025","unstructured":"Cejalvo And\u00fajar, J. M. et al. Optimizing therapeutic approaches for HR+\/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4\/6 inhibitor progression. Cancer Drug Resist. 2025, 5 (2025).","journal-title":"Cancer Drug Resist."},{"key":"968_CR9","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","volume":"25","author":"IM Browne","year":"2024","unstructured":"Browne, I. M. et al. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 25, e139\u2013e151 (2024).","journal-title":"Lancet Oncol."},{"key":"968_CR10","doi-asserted-by":"publisher","first-page":"e38508","DOI":"10.1097\/MD.0000000000038508","volume":"103","author":"L Pan","year":"2024","unstructured":"Pan, L. et al. HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: a review. Medicine 103, e38508 (2024).","journal-title":"Medicine"},{"key":"968_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04841-w","volume":"22","author":"M Tufail","year":"2024","unstructured":"Tufail, M. et al. Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway. J. Transl. Med. 22, 15 (2024).","journal-title":"J. Transl. Med."},{"key":"968_CR12","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer. N. Engl. J. Med. 380, 1929\u20131940 (2019).","journal-title":"N. Engl. J. Med."},{"key":"968_CR13","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","volume":"25","author":"HS Rugo","year":"2024","unstructured":"Rugo, H. S. et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 25, e629\u2013e638 (2024).","journal-title":"Lancet Oncol."},{"key":"968_CR14","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"F-C Bidard","year":"2022","unstructured":"Bidard, F.-C. et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: results from the randomized phase III EMERALD trial. J. Clin. Oncol. 40, 3246\u20133256 (2022).","journal-title":"J. Clin. Oncol."},{"key":"968_CR15","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.20.02151","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung, N. M. et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J. Clin. Oncol. 38, 4274\u20134282 (2020).","journal-title":"J. Clin. Oncol."},{"key":"968_CR16","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner, N. C. et al. Capivasertib in hormone receptor\u2013positive advanced breast cancer. N. Engl. J. Med. 388, 2058\u20132070 (2023).","journal-title":"N. Engl. J. Med."},{"key":"968_CR17","doi-asserted-by":"crossref","unstructured":"Migliaccio, I. et al. Circulating biomarkers of CDK4\/6 inhibitors response in hormone receptor positive and HER2 negative breast cancer. Cancers 13, 2640 (2021).","DOI":"10.3390\/cancers13112640"},{"key":"968_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2147\/BCTT.S340741","volume":"15","author":"A H\u00f6ller","year":"2023","unstructured":"H\u00f6ller, A., Nguyen-Str\u00e4uli, B. D., Frauchiger-Heuer, H. & Ring, A. Diagnostic and prognostic biomarkers of luminal breast cancer: where are we now? Breast Cancer. Targets Ther. 15, 525\u2013540 (2023).","journal-title":"Breast Cancer. Targets Ther."},{"key":"968_CR19","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1200\/JCO.2024.42.16_suppl.1029","volume":"42","author":"FG Rojo Todo","year":"2024","unstructured":"Rojo Todo, F. G. et al. Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+\/HER2- metastatic breast cancer (MBC) enrolled in the GEICAM\/2014-12 FLIPPER trial. J. Clin. Oncol. 42, 1029 (2024).","journal-title":"J. Clin. Oncol."},{"key":"968_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"B Fran\u00e7ois-Cl\u00e9ment","year":"2025","unstructured":"Fran\u00e7ois-Cl\u00e9ment, B. et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N. Engl. J. Med. 393, 569\u2013580 (2025).","journal-title":"N. Engl. J. Med."},{"key":"968_CR21","doi-asserted-by":"crossref","unstructured":"Dieci, M. V., Miglietta, F., Griguolo, G. & Guarneri, V. Biomarkers for HER2-positive metastatic breast cancer: beyond hormone receptors. Cancer Treat. Rev. 88, 102064 (2020).","DOI":"10.1016\/j.ctrv.2020.102064"},{"key":"968_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/annonc\/mdz036","volume":"30","author":"R Condorelli","year":"2019","unstructured":"Condorelli, R. et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO scale for clinical actionability of molecular targets (ESCAT). Ann. Oncol. 30, 365\u2013373 (2019).","journal-title":"Ann. Oncol."},{"key":"968_CR23","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner, N. C. et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N. Engl. J. Med. 391, 1584\u20131596 (2024).","journal-title":"N. Engl. J. Med."},{"key":"968_CR24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon, D. et al. Ribociclib plus endocrine therapy in early breast cancer. N. Engl. J. Med. 390, 1080\u20131091 (2024).","journal-title":"N. Engl. J. Med."},{"key":"968_CR25","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.22.01063","volume":"40","author":"NL Henry","year":"2022","unstructured":"Henry, N. L. et al. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. J. Clin. Oncol. 40, 3205\u20133221 (2022).","journal-title":"J. Clin. Oncol."},{"key":"968_CR26","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1158\/2159-8290.CD-20-1647","volume":"11","author":"P Aftimos","year":"2021","unstructured":"Aftimos, P. et al. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. Cancer Discov. 11, 2796\u20132811 (2021).","journal-title":"Cancer Discov."},{"key":"968_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-023-07010-1","volume":"201","author":"J Rosin","year":"2023","unstructured":"Rosin, J., Svegrup, E., Valachis, A. & Zerdes, I. Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis. Breast Cancer Res. Treat. 201, 161\u2013169 (2023).","journal-title":"Breast Cancer Res. Treat."},{"key":"968_CR28","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.3390\/cancers12123797","volume":"12","author":"A Mesquita","year":"2020","unstructured":"Mesquita, A., Costa, J. L. & Schmitt, F. Utility of circulating tumor DNA in different clinical scenarios of breast cancer. Cancers 12, 3797 (2020).","journal-title":"Cancers"},{"key":"968_CR29","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3390\/curroncol29030113","volume":"29","author":"BS Sheffield","year":"2022","unstructured":"Sheffield, B. S. et al. Point of care molecular testing: community-based rapid next-generation sequencing to support cancer care. Curr. Oncol. 29, 1326\u20131334 (2022).","journal-title":"Curr. Oncol."},{"key":"968_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00428-020-02928-z","volume":"478","author":"K Dufraing","year":"2021","unstructured":"Dufraing, K. et al. Biomarker testing in oncology \u2013 Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL. Virchows Arch. 478, 553\u2013565 (2021).","journal-title":"Virchows Arch."},{"key":"968_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96644-6","volume":"11","author":"J Corn\u00e9","year":"2021","unstructured":"Corn\u00e9, J. et al. Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients. Sci. Rep. 11, 17316 (2021).","journal-title":"Sci. Rep."},{"key":"968_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00626-6","volume":"10","author":"O Amato","year":"2024","unstructured":"Amato, O., Giannopoulou, N. & Ignatiadis, M. Circulating tumor DNA validity and potential uses in metastatic breast cancer. NPJ Breast Cancer 10, 21 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"968_CR33","unstructured":"Wales Cancer Network. PIK3CA-mutated breast cancer clinical guidance document [Internet; cited 2025 Jun]. Available from: https:\/\/executive.nhs.wales\/functions\/networks-and-planning\/cancer\/wcn-documents\/mutatedbreast-cancer-clinical-guidance-document\/\/."},{"key":"968_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2220\/biomedres.44.161","volume":"44","author":"T NAGASHIMA","year":"2023","unstructured":"NAGASHIMA, T. et al. Comparative analysis of tumor content estimation methods based on simu- lated tumor samples identified their impact on somatic variant detection in cancer whole genome sequencing. Biomed. Res. 44, 161\u2013171 (2023).","journal-title":"Biomed. Res."},{"key":"968_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.32074\/1591-951X-1215","volume":"117","author":"C Marchi\u00f2","year":"2025","unstructured":"Marchi\u00f2, C. et al. Part I \u2013 Pre-analytical phase. Pathologica 117, 5 (2025).","journal-title":"Pathologica"},{"key":"968_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01470-y","volume":"8","author":"HT Shin","year":"2017","unstructured":"Shin, H. T. et al. Prevalence and detection of low-allele-fraction variants in clinical cancer samples. Nat. Commun. 8, 1377 (2017).","journal-title":"Nat. Commun."},{"key":"968_CR37","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.anndiagpath.2013.02.001","volume":"17","author":"VM Singh","year":"2013","unstructured":"Singh, V. M. et al. Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Ann. Diagn. Pathol. 17, 322\u2013326 (2013).","journal-title":"Ann. Diagn. Pathol."},{"key":"968_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.nbt.2019.07.005","volume":"54","author":"O Kofanova","year":"2020","unstructured":"Kofanova, O. et al. Standardization of the preanalytical phase of DNA extraction from fixed tissue for next-generation sequencing analyses. N. Biotechnol. 54, 52\u201361 (2020).","journal-title":"N. Biotechnol."},{"key":"968_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4132\/KoreanJPathol.2014.48.1.36","volume":"48","author":"SK Nam","year":"2014","unstructured":"Nam, S. K. et al. Effects of fixation and storage of human tissue samples on nucleic acid preservation. Korean J. Pathol. 48, 36\u201342 (2014).","journal-title":"Korean J. Pathol."},{"key":"968_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ab.2017.11.004","volume":"542","author":"S Nikolaev","year":"2018","unstructured":"Nikolaev, S., Lemmens, L., Koessler, T., Blouin, J.-L. & Nouspikel, T. Circulating tumoral DNA: preanalytical validation and quality control in a diagnostic laboratory. Anal. Biochem. 542, 34\u201339 (2018).","journal-title":"Anal. Biochem."},{"key":"968_CR41","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jmoldx.2017.06.004","volume":"19","author":"C Alidousty","year":"2017","unstructured":"Alidousty, C. et al. Comparison of blood collection tubes from three different manufacturers for the collection of cell-free DNA for liquid biopsy mutation testing. J. Mol. Diagn. 19, 801\u2013804 (2017).","journal-title":"J. Mol. Diagn."},{"key":"968_CR42","doi-asserted-by":"publisher","first-page":"e0166354","DOI":"10.1371\/journal.pone.0166354","volume":"11","author":"I Medina Diaz","year":"2016","unstructured":"Medina Diaz, I. et al. Performance of streck cfDNA blood collection tubes for liquid biopsy testing. PLoS ONE 11, e0166354 (2016).","journal-title":"PLoS ONE"},{"key":"968_CR43","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-19-3015","volume":"26","author":"SR Greytak","year":"2020","unstructured":"Greytak, S. R. et al. Harmonizing cell-free DNA collection and processing practices through evidence-based guidance. Clin. Cancer Res. 26, 3104\u20133109 (2020).","journal-title":"Clin. Cancer Res."},{"key":"968_CR44","doi-asserted-by":"crossref","unstructured":"Lippi, G., Guidi, G. C., Mattiuzzi, C. & Plebani, M. Preanalytical variability: the dark side of the moon in laboratory testing. Clin. Chem. Lab. Med. 44, 358\u2013365 (2006).","DOI":"10.1515\/CCLM.2006.073"},{"key":"968_CR45","doi-asserted-by":"publisher","unstructured":"Liu, M. C. et al. Longitudinal shifts of solid tumor and liquid biopsy sequencing concordance in metastatic breast cancer. JCO Precis. Oncol. e2100321 https:\/\/doi.org\/10.1200\/PO.21.00321 (2022).","DOI":"10.1200\/PO.21.00321"},{"key":"968_CR46","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","volume":"21","author":"NC Turner","year":"2020","unstructured":"Turner, N. C. et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 21, 1296\u20131308 (2020).","journal-title":"Lancet Oncol."},{"key":"968_CR47","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ejso.2017.01.010","volume":"43","author":"L Cabel","year":"2017","unstructured":"Cabel, L. et al. Circulating tumor cells and circulating tumor DNA: what surgical oncologists need to know? Eur. J. Surgical Oncol. 43, 949\u2013962 (2017).","journal-title":"Eur. J. Surgical Oncol."},{"key":"968_CR48","first-page":"1044","volume":"12","author":"F Bi","year":"2020","unstructured":"Bi, F. et al. Circulating tumor DNA in colorectal cancer: opportunities and challenges. Am. J. Transl. Res. 12, 1044\u20131055 (2020).","journal-title":"Am. J. Transl. Res."},{"key":"968_CR49","doi-asserted-by":"crossref","unstructured":"Martens, G. A. et al. Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancer. ESMO Open 9, 102235 (2024).","DOI":"10.1016\/j.esmoop.2024.102235"},{"key":"968_CR50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ejca.2017.01.017","volume":"75","author":"MJ Duffy","year":"2017","unstructured":"Duffy, M. J. et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur. J. Cancer 75, 284\u2013298 (2017).","journal-title":"Eur. J. Cancer"},{"key":"968_CR51","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","volume":"25","author":"NB Leighl","year":"2019","unstructured":"Leighl, N. B. et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non\u2013small cell lung cancer. Clin. Cancer Res. 25, 4691\u20134700 (2019).","journal-title":"Clin. Cancer Res."},{"key":"968_CR52","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1200\/JCO.2015.61.1459","volume":"33","author":"C Van Poznak","year":"2015","unstructured":"Van Poznak, C. et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 33, 2695\u20132704 (2015).","journal-title":"J. Clin. Oncol."},{"key":"968_CR53","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/jnci\/djt282","volume":"105","author":"MYC Polley","year":"2013","unstructured":"Polley, M. Y. C. et al. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J. Natl. Cancer Inst. 105, 1677\u20131683 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"968_CR54","doi-asserted-by":"publisher","first-page":"31904","DOI":"10.18632\/oncotarget.25881","volume":"9","author":"A Sato","year":"2018","unstructured":"Sato, A. et al. Investigation of appropriate pre-analytical procedure for circulating free DNA from liquid biopsy. Oncotarget 9, 31904\u201331914 (2018).","journal-title":"Oncotarget"},{"key":"968_CR55","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/clinchem\/hvad194","volume":"70","author":"P van der Leest","year":"2024","unstructured":"van der Leest, P. & Schuuring, E. Critical factors in the analytical work flow of circulating tumor DNA-based molecular profiling. Clin. Chem. 70, 220\u2013233 (2024).","journal-title":"Clin. Chem."},{"key":"968_CR56","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton, G. M. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31, 1023\u20131031 (2013).","journal-title":"Nat. Biotechnol."},{"key":"968_CR57","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/joim.12897","volume":"286","author":"G Barbany","year":"2019","unstructured":"Barbany, G. et al. Cell-free tumour DNA testing for early detection of cancer \u2013 a potential future tool. J. Intern. Med. 286, 118\u2013136 (2019).","journal-title":"J. Intern. Med."},{"key":"968_CR58","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895\u20131902 (2018).","journal-title":"Ann. Oncol."},{"key":"968_CR59","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jmoldx.2017.11.010","volume":"20","author":"SS Hung","year":"2018","unstructured":"Hung, S. S. et al. Assessment of capture and amplicon-based approaches for the development of a targeted next-generation sequencing pipeline to personalize lymphoma management. J. Mol. Diagn. 20, 203\u2013214 (2018).","journal-title":"J. Mol. Diagn."},{"key":"968_CR60","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/humu.22825","volume":"36","author":"E Samorodnitsky","year":"2015","unstructured":"Samorodnitsky, E. et al. Evaluation of hybridization capture versus amplicon-based methods for whole-exome sequencing. Hum. Mutat. 36, 903\u2013914 (2015).","journal-title":"Hum. Mutat."},{"key":"968_CR61","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.1016\/j.jtho.2019.08.307","volume":"14","author":"L Sholl","year":"2019","unstructured":"Sholl, L. MS02.03 achieving effective lung cancer genotyping while balancing constrained resources. J. Thorac. Oncol. 14, S150\u2013S151 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"968_CR62","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/j.jtho.2019.08.236","volume":"14","author":"L Sholl","year":"2019","unstructured":"Sholl, L. IBS18.02 tests by next generation sequencing. J. Thorac. Oncol. 14, S109\u2013S110 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"968_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.644737","volume":"11","author":"N Fusco","year":"2021","unstructured":"Fusco, N. et al. PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer. Front. Oncol. 11, 644737 (2021).","journal-title":"Front. Oncol."},{"key":"968_CR64","doi-asserted-by":"crossref","unstructured":"van de Haar, J., Hoes, L. & Voest, E. Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine. ESMO Open 4, e000516 (2019).","DOI":"10.1136\/esmoopen-2019-000516"},{"key":"968_CR65","doi-asserted-by":"crossref","unstructured":"Petrackova, A. et al. Standardization of sequencing coverage depth in NGS: recommendation for detection of clonal and subclonal mutations in cancer diagnostics. Front. Oncol. 9, 851 (2019).","DOI":"10.3389\/fonc.2019.00851"},{"key":"968_CR66","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1111\/cas.13696","volume":"109","author":"T Shimoi","year":"2018","unstructured":"Shimoi, T. et al. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. Cancer Sci. 109, 2558\u20132566 (2018).","journal-title":"Cancer Sci."},{"key":"968_CR67","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-024-07376-w","volume":"207","author":"MA Bhave","year":"2024","unstructured":"Bhave, M. A. et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(\u2212) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res. Treat. 207, 599\u2013609 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"968_CR68","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/jclinpath-2014-202404","volume":"67","author":"IA Cree","year":"2014","unstructured":"Cree, I. A. et al. Guidance for laboratories performing molecular pathology for cancer patients. J. Clin. Pathol. 67, 923 (2014).","journal-title":"J. Clin. Pathol."},{"key":"968_CR69","doi-asserted-by":"publisher","first-page":"e12566","DOI":"10.1200\/JCO.2024.42.16_suppl.e12566","volume":"42","author":"N Rohatgi","year":"2024","unstructured":"Rohatgi, N. et al. Molecular profiling in ABC: is complementary testing with tissue and plasma necessary and clinically relevant? J. Clin. Oncol. 42, e12566\u2013e12566 (2024).","journal-title":"J. Clin. Oncol."},{"key":"968_CR70","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.annonc.2024.04.008","volume":"35","author":"J Garc\u00eda-Foncillas","year":"2024","unstructured":"Garc\u00eda-Foncillas, J. et al. Overcoming barriers in biomarker testing. Letter to the Editor regarding: ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe, by A. Bayle et al. Ann. Oncol. 35, 677\u2013678 (2024).","journal-title":"Ann. Oncol."},{"key":"968_CR71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2020.39.28_suppl.16","volume":"39","author":"SD Goldfarb","year":"2025","unstructured":"Goldfarb, S. D. et al. Biomarker testing patterns and identification of barriers to testing for homologous recombination deficiencies across four advanced-stage solid tumors in a multicommunity practice setting. J. Clin. Oncol. 39, 16 (2025).","journal-title":"J. Clin. Oncol."},{"key":"968_CR72","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3390\/curroncol31030103","volume":"31","author":"S Snow","year":"2024","unstructured":"Snow, S. et al. Barriers and unequal access to timely molecular testing results: addressing the inequities in cancer care delays across Canada. Curr. Oncol. 31, 1359\u20131375 (2024).","journal-title":"Curr. Oncol."},{"key":"968_CR73","doi-asserted-by":"crossref","unstructured":"Sirisena, N. D. & Dissanayake, V. H. W. Strategies for genomic medicine education in low- and middle-income countries. Front. Genet. 10, 2019 (2019).","DOI":"10.3389\/fgene.2019.00944"},{"key":"968_CR74","doi-asserted-by":"publisher","unstructured":"Kratz, J. et al. Incorporating genomics into the care of patients with advanced breast cancer. in American Society of Clinical Oncology Educational Book, 56\u201364, https:\/\/doi.org\/10.1200\/EDBK_200731 (2025).","DOI":"10.1200\/EDBK_200731"},{"key":"968_CR75","doi-asserted-by":"crossref","unstructured":"Rudell, E. et al. Abstract P6-05-15: standard of care for HR+\/HER2- breast cancer: integrating the \u201cYale model shared decision-making multidisciplinary team solution\u201d into the practice setting. Cancer Res. 83, P6-05-15 (2023).","DOI":"10.1158\/1538-7445.SABCS22-P6-05-15"},{"key":"968_CR76","doi-asserted-by":"crossref","unstructured":"Tolaney, S. M. et al. Abstract P1-15-05: identifying educational needs and areas for improvement in the management of HR+, HER2- breast cancer using cyclin-dependent kinase 4\/6 inhibitors. Cancer Res. 80, P1-15-05 (2020).","DOI":"10.1158\/1538-7445.SABCS19-P1-15-05"},{"key":"968_CR77","doi-asserted-by":"publisher","first-page":"e001583","DOI":"10.1136\/jitc-2020-001583","volume":"8","author":"B Gastman","year":"2020","unstructured":"Gastman, B. et al. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J. Immunother. Cancer 8, e001583 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"968_CR78","doi-asserted-by":"crossref","unstructured":"Earl, J. et al. A standardized liquid biopsy preanalytical protocol for downstream circulating-free DNA applications. J. Vis. Exp. 187, 10.3791\/64123 (2022).","DOI":"10.3791\/64123"},{"key":"968_CR79","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/OP.2023.19.11_suppl.559","volume":"19","author":"M Cruz-Tanner","year":"2023","unstructured":"Cruz-Tanner, M., Canavan, J., Kiley, L., Montes, R. & Ronnen, E. A. Enhancing precision medicine testing process in a breast cancer population of a community oncology practice: use of oncology patient navigators (OPN) and a molecular processing team (MPT) to improve germline testing. JCO Oncol. Pract. 19, 559 (2023).","journal-title":"JCO Oncol. Pract."},{"key":"968_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01284-9","volume":"22","author":"O Mart\u00ednez-S\u00e1ez","year":"2020","unstructured":"Mart\u00ednez-S\u00e1ez, O. et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 22, 45 (2020).","journal-title":"Breast Cancer Res."},{"key":"968_CR81","unstructured":"European Medicine Agency. Itoveby Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/itovebi-epar-medicine-overview_en.pdf."},{"key":"968_CR82","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/jmp2010005","volume":"2","author":"C Criscitiello","year":"2021","unstructured":"Criscitiello, C., Marra, A. & Curigliano, G. PIK3CA mutation assessment in HR+\/HER2\u2212 metastatic breast cancer: overview for oncology clinical practice. J. Mol. Pathol. 2, 42\u201354 (2021).","journal-title":"J. Mol. Pathol."},{"key":"968_CR83","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s12282-024-01639-6","volume":"32","author":"H Tada","year":"2025","unstructured":"Tada, H. et al. Clinicopathogenomic analysis of PI3K\/AKT\/PTEN-altered luminal metastatic breast cancer in Japan. Breast Cancer 32, 208\u2013216 (2025).","journal-title":"Breast Cancer"},{"key":"968_CR84","unstructured":"Tuqrap Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/truqap-epar-product-information_en.pdf."},{"key":"968_CR85","unstructured":"Piqray Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/piqray-epar-product-information_en.pdf."},{"key":"968_CR86","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo, H. S. et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res. Treat. 174, 719\u2013729 (2019).","journal-title":"Breast Cancer Res. Treat."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00968-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00968-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00968-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:06:53Z","timestamp":1785841613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00968-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["968"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00968-3","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.M. has received personal consultancy fees from Menarini, Roche, and Illumina, and speaker fees from Daiichi Sankyo and Veracyte, outside the submitted work. F.R. reports honoraria and participation in advisory boards\/consultation for AstraZeneca, Eli Lilly, Menarini Stemline, Novartis, Pfizer, MSD, Merck, Amgen, Janssen, Bristol Myers Squibb (BMS), Astellas, AbbVie, BeiGene, SOPHiA GENETICS, Agilent, and Roche; and research funding from Pfizer, Astellas, Menarini Stemline, and AstraZeneca. E.R.C. reports honoraria from AstraZeneca, Eli Lilly, Guardant, Menarini Stemline, Novartis, Pfizer, and Roche; participation in advisory boards\/consultation for AstraZeneca, Eli Lilly, NanoString, Pfizer, and Roche; conference fees\/travel\/accommodation from Roche and Novartis; an educational grant from Daiichi Sankyo; and research support from SECA. B.B. reports honoraria and participation in advisory boards\/consultation for AstraZeneca, Incyte, Menarini Stemline, Novartis, MSD, Merck, Amgen, Johnson & Johnson, BMS, Pfizer, Thermo Fisher, and Roche; and research funding from Roche, Thermo Fisher, and AstraZeneca. C.F. has received honoraria and\/or fees from Pfizer, Roche, Eisai, AstraZeneca, Eli Lilly, MSD, Novartis, Gilead, and Veracyte. F.S. declares no competing interests. C.M. and F.S. are Associate Editors of npj Breast Cancer. C.M. and F.S. were not involved in the journal\u2019s review of, or decisions related to, this manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"100"}}